Immix Biopharma Stock Price Prediction
| IMMX Stock | USD 2.11 0.14 7.11% |
Oversold Vs Overbought
47
Oversold | Overbought |
EPS Estimate Next Quarter (0.14) | EPS Estimate Current Year (0.64) | EPS Estimate Next Year (0.55) | Wall Street Target Price 7 | EPS Estimate Current Quarter (0.16) |
Using Immix Biopharma hype-based prediction, you can estimate the value of Immix Biopharma from the perspective of Immix Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Immix Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Immix because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Immix Biopharma after-hype prediction price | USD 2.1 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Immix |
Immix Biopharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Immix Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Immix Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Immix Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Immix Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Immix Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Immix Biopharma's historical news coverage. Immix Biopharma's after-hype downside and upside margins for the prediction period are 0.11 and 8.31, respectively. We have considered Immix Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Immix Biopharma is risky at this time. Analysis and calculation of next after-hype price of Immix Biopharma is based on 3 months time horizon.
Immix Biopharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Immix Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immix Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Immix Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.23 | 6.21 | 0.01 | 0.01 | 4 Events / Month | 8 Events / Month | In about 4 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
2.11 | 2.10 | 0.47 |
|
Immix Biopharma Hype Timeline
Immix Biopharma is currently traded for 2.11. The entity has historical hype elasticity of -0.01, and average elasticity to hype of competition of 0.01. Immix is expected to decline in value after the next headline, with the price expected to drop to 2.1. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.47%, whereas the daily expected return is currently at 0.23%. The volatility of related hype on Immix Biopharma is about 12848.28%, with the expected price after the next announcement by competition of 2.12. About 40.0% of the company shares are held by company insiders. The book value of Immix Biopharma was currently reported as 0.82. The company recorded a loss per share of 0.84. Immix Biopharma had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be in about 4 days. Check out Immix Biopharma Basic Forecasting Models to cross-verify your projections.Immix Biopharma Related Hype Analysis
Having access to credible news sources related to Immix Biopharma's direct competition is more important than ever and may enhance your ability to predict Immix Biopharma's future price movements. Getting to know how Immix Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Immix Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ZVSA | ZyVersa Therapeutics | (0.1) | 4 per month | 0.00 | (0.15) | 7.57 | (9.60) | 78.93 | |
| HEPA | Hepion Pharmaceuticals | (0.02) | 4 per month | 0.00 | (0.05) | 8.06 | (8.11) | 33.54 | |
| AVRO | AVROBIO | 0.05 | 5 per month | 1.89 | 0.01 | 4.11 | (3.17) | 14.20 | |
| EFTR | Effector Therapeutics | (0.06) | 4 per month | 0.00 | (0.31) | 8.70 | (27.78) | 88.91 | |
| CNSP | Cns Pharmaceuticals | (0.01) | 6 per month | 0.00 | (0.06) | 9.09 | (8.33) | 39.29 | |
| NAVB | Navidea Biopharmaceuticals | 0.00 | 0 per month | 0.00 | (0.15) | 12.50 | (12.50) | 40.40 | |
| SONN | Sonnet Biotherapeutics Holdings | 1.15 | 6 per month | 0.00 | (0.17) | 12.31 | (9.79) | 37.58 | |
| FRLN | Freeline Therapeutics Holdings | (0.58) | 1 per month | 0.00 | (0.02) | 14.23 | (13.11) | 72.38 | |
| ENVB | Enveric Biosciences | 0.08 | 6 per month | 0.00 | (0.15) | 6.25 | (7.50) | 28.33 | |
| CWBR | CohBar Inc | 0.07 | 3 per month | 5.34 | 0.08 | 5.73 | (5.59) | 250.97 | |
| ELEV | Elevation Oncology | (0.02) | 9 per month | 0.00 | (0.05) | 5.77 | (8.22) | 22.21 | |
| OCEA | Ocean Biomedical | 0.02 | 3 per month | 0.00 | (0.08) | 7.46 | (6.06) | 28.33 |
Immix Biopharma Additional Predictive Modules
Most predictive techniques to examine Immix price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Immix using various technical indicators. When you analyze Immix charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Immix Biopharma Predictive Indicators
The successful prediction of Immix Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Immix Biopharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Immix Biopharma based on analysis of Immix Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Immix Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Immix Biopharma's related companies. | 2010 | 2023 | 2024 (projected) | Gross Profit Margin | 1.0 | 0.9 | 0.8 | Net Profit Margin | 0.0919 | 0.0827 | 0.0735 |
Story Coverage note for Immix Biopharma
The number of cover stories for Immix Biopharma depends on current market conditions and Immix Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Immix Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Immix Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Immix Biopharma Short Properties
Immix Biopharma's future price predictability will typically decrease when Immix Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Immix Biopharma often depends not only on the future outlook of the potential Immix Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immix Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 17.3 M | |
| Cash And Short Term Investments | 17.5 M |
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.